Health Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit By Ian Lyall 02/09
Health Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials By Ian Lyall 02/09
Health Ondine Biomedical share price rallies following 40% drop in surgical infections By Ian Lyall 01/09
Health Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy By Ian Lyall 01/09
Health GENinCode shares rise over 18% intraday after coronary disease test results presented at European conference By Ian Lyall 28/08
Health Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris By Ian Lyall 28/08
Health Stifel reiterates Buy on Faron Pharmaceuticals after cash update secures runway to key trial readout By Ian Lyall 26/08
Health HaemaLogiX advances KOALA blood cancer trial after safely dosing first patient By Ian Lyall 26/08
Health Faron targets second-half start for pivotal blood cancer trial after latest investment round By Ian Lyall 26/08
Health Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug By Proactive 26/08